AS is a rare inflammatory disease causing spine pain and stiffness. Symptoms typically appear in 20-30 year olds, starting in lower back. No cure exists, treatments include medication, exercise, and physical therapy. Most patients have HLA-B27 antigen, likely genetic and environmental factors
Sulfasalazine is a DMARD used to treat ulcerative colitis, rheumatoid arthritis, and juvenile rheumatoid arthritis. It works by reducing inflammation and limiting joint damage in rheumatoid arthritis. Contains 5-aminosalicylic acid and antibiotic sulfapyridine linked by a bond
ASDAS combines five disease activity variables into one composite index. Two versions exist: CRP-based (preferred) and ESR-based (alternative). Variables include back pain, morning stiffness, patient global, and peripheral pain. All items use visual analogue or numerical rating scales
Two systematic literature reviews conducted on axSpA treatment. Task force meeting reviewed evidence and updated recommendations. 15 recommendations agreed, including 5 overarching principles
Psoriatic arthritis is a long-term inflammatory arthritis associated with psoriasis. Affects up to 30% of people with psoriasis, equally in men and women. Occurs in both children and adults, less common in Asian and African descent
AS is a type of arthritis affecting spine joints, typically between pelvis and spine. Affects 0.1-0.8% of population, with peak onset between 20-30 years. More common in Northern Europeans, least in Afro-Caribbean descent